<DOC>
	<DOCNO>NCT01191684</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gene-modified virus may help body build effective immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient colorectal , stomach , pancreatic cancer .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Colorectal , Stomach , Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To establish whether 2 vaccine dose level modify vaccinia virus ankara vaccine express p53 ( MVAp53 ) vaccine safe well tolerated patient p53 over-expressing solid tumor malignancy . SECONDARY OBJECTIVES : I . To provide preliminary evidence enhance cellular humoral immunity p53 . OUTLINE : This phase I , dose-escalation trial modify vaccinia virus ankara vaccine express p53 ( MVAp53 ) .Patients receive MVAp53 subcutaneously ( SC ) day 0 , 21 , 42 absence unacceptable toxicity . After completion study treatment , patient follow annually 5 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients unresectable chemotherapy resistant primary recurrent carcinoma colorectal , gastric pancreatic origin There must pathologic evidence malignancy soft tissue component tumor evident CT scan image physical examination Patient must able give informed consent There must anticipate survival least 3 month Performance status 80100 ( Karnofsky performance status ) WBC count &gt; = 3,000uL Platelet count &gt; = 100,000uL Prothrombin time partial thromboplastin time &lt; = 1.5 time upper limit normal Women childbearing potential must negative pregnancy test ; woman men childbearing potential must agree use adequate contraception ( hormonal barrier method birth control abstinence ) prior study entry six month follow duration study participation ; woman become pregnant suspect pregnant participate trial , inform treat physician immediately Patients asymptomatic small volume bone disease likely require radiation therapy period vaccine trial eligible Hemoglobin level &gt; 9g/dL There must evidence p53 expression immunohistochemistry &gt; 10 % cell within tumor strongly positive Patients colorectal cancer need fail respond 5FU base therapy oxaliplatin , irinotecan well epidermal growth factor receptor ( EGFR ) direct therapy ( appropriate ) ; patient gastric cancer need progress standard first line chemotherapy chemoradiotherapy Herceptin base therapy ( appropriate ) ; patient pancreatic cancer fail respond least 1 chemotherapy regimen Diagnosis associate immunodeficiency , include HIV Prior radiation 50 % nodal group Concurrent use corticosteroid History another malignancy , nonmelanoma skin cancer past 2 year Recent major surgery Serious intercurrent illness Temperature &gt; = 101F within 3 day prior initial injection Pregnancy lactation Clinically evident brain metastasis Autoimmune disease HIV seropositivity refusal hear result HIV test Receipt organ graft History severe environmental allergy History severe neurological , cardiovascular , renal , hepatic , endocrine , respiratory , bone marrow dysfunction require frequent reevaluation , management physician Patients history congestive heart failure coronary artery disease resolve bypass stent History myopericarditis Known family history LiFraumeni syndrome Allergy egg protein Chemotherapy radiation within 4 week precede enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>